De-Escalation of Trastuzumab Remains Controversial in HER2+ Breast Cancer

After more than 7 years of follow-up, the phase III PHARE trial failed to show that 6 months of adjuvant trastuzumab therapy was noninferior to 12 months in patients with HER2+ early breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news